The discontinuation of STRIDES is a rare stumble for the next-generation obesity field and comes just weeks after Amgen ...
Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a ...
Unlike its rivals, which require weekly injections, MariTide offers the potential for monthly or less frequent dosing ...
Wall Street is chewing over data on Amgen’s weight loss injection, MariTde. Meanwhile, GE HealthCare will acquire a Japanese ...
The company, which raised $84 million, sees validation of its GIP-blocking approach to weight loss in Amgen's recent MariTide ...
By Gina Kolata The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 percent of their weight in a year. The drug, MariTide ...
The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...
The biotech disclosed Friday plans to terminate a Phase 2 study testing azelaprag with tirzepatide for weight loss following ...
Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.
Amgen said Tuesday that that its drug, MariTide, led to an average of roughly 20% weight loss over a year in the Phase 2 study in participants who had obesity or who were overweight without type 2 ...
The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback